Regression to normoalbuminuria (< 30 mg/ day) was more frequent in the Karvea 300 mg group (34%) than in the placebo group (21%).
Normoalbuminuuria (< 30 mg/ ööpäevas) tekkis sagedamini Karvea 300 mg grupis (34%) kui platseebogrupis (21%).